- Topic
8k Popularity
7k Popularity
10k Popularity
49k Popularity
5k Popularity
33k Popularity
21k Popularity
33k Popularity
150k Popularity
- Pin
- GT Airdrop Is Live! 1.92M GT Burned in Q2, Worth Over $39M
🎁 Complete simple tasks, get up to 13.2 GT per user
📅 From July 8 to July 20
👉 Join now + trade futures to qualify: https://www.gate.com/campaigns/1431
- 📢 #Gate Square Writing Contest Phase 1# is now officially launched!
Share your unique insights on the CROSS project and stand a chance to win $500 worth of CROSS rewards!
💰 Rewards:
1st Prize (1 winner): $150 worth of CROSS
2nd Prize (3 winners): $50 worth of CROSS each
3rd Prize (10 winners): $20 worth of CROSS each
👉 How to Participate:
1. Publish your unique insights on the CROSS project in Gate Square.
2. Add the tag #Gate Square Writing Contest Phase 1# to your post (minimum of 300 words).
3. Share your article or insights on X with the tags: Gate Square & CROSS.
Essay Content Directio
- 🎉 #Gate xStocks Trading Share# Posting Event Is Ongoing!
📝 Share your trading experience on Gate Square to unlock $1,000 rewards!
🎁 5 top Square creators * $100 Futures Voucher
🎉 Share your post on X – Top 10 posts by views * extra $50
How to Participate:
1️⃣ Follow Gate_Square
2️⃣ Make an original post (at least 20 words) with #Gate xStocks Trading Share#
3️⃣ If you share on Twitter, submit post link here: https://www.gate.com/questionnaire/6854
Note: You may submit the form multiple times. More posts, higher chances to win!
📅 End at: July 9, 16:00 UTC
Show off your trading on Gate Squ
- 🚀 Calling all Gate Square content creators!
Join the Gate 2025 Mid-Year Gala to become a top creator
Win Gate x Red Bull merch, $1,000 Futures Vouchers, VIP+1, and fan-exclusive rewards!
Sign up now 👉 www.gate.com/activities/community-vote
#GateSquare#
Novo Nordisk: 7.2mg semaglutide phase 3 clinical trial met the primary endpoint with a weight loss of 20.7% at 72 weeks.
On January 18, Jins data reported that on January 17 local time, Novo Nordisk announced the main results of the 3b phase clinical trial STEP UP. In the STEP UP obesity trial, subcutaneous injection of 7.2mg semaglutide once a week resulted in a weight loss of 20.7% at 72 weeks, and a weight loss of 18.7% regardless of treatment compliance. The trial met its primary endpoint, with 7.2mg semaglutide showing statistically significant and superior weight loss compared to placebo at 72 weeks.